Designers of future trials of TG-lowering therapy may want to consider enrolling patients with a wider range of TG levels than in previous studies if there is no prior history of pancreatitis. This is the advice of Professor Paul Ridker (Brigham and Women’s Hospital, Boston, USA) and colleagues in the light of an analysis of major cardiovascular (CV) events and death data according to baseline TG levels.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
